Established on an area exceeding more than 4000 m2 in Riyadh, Genalive is the largest specialized laboratory in the kingdom that provides comprehensive solutions to its patients, utilizing the most advanced diagnostic techniques.

 

The laboratory aims to localize specialized genetic testing in addition to offering routine lab testing with a menu that includes clinical pathology (hematology, chemistry, immunochemistry), as well as reproductive, hereditary and oncology (cancer) genetics.

 

r. Saeed Al-Amoudi, CEO of Genalive Medical Laboratory expressed how glad and grateful he is on launching Genalive Medical Laboratory. He explained “Genalive is the first of its kind in the kingdom to have established the largest data centre with advanced bioinformatics capabilities in the private sector. This will greatly facilitate fast and accurate analysis of data in order to detect genetic variants while ensuring data privacy and security for all our patients and visitors.”

 

Dr. Al-Amoudi also clarified that these tests are a key enabler in genetic disease prevention as they provide individuals with the opportunity of early screening before marriage, before or during pregnancy, as well as pre-implantation. Furthermore, Genalive will offer – in addition to testing – genetic counseling, which will enable individuals to make informed decisions concerning their health and the health of their families, which will reflect positively on the quality of life and well-being of society.

 

Al-Amoudi further emphasized that Genalive will directly support in achieving the ambitious objectives of the Health Sector Transformation Program in several aspects such as: localization of genetic testing, which will contribute to reducing the kingdom’s expenditure on healthcare and send-out services, cultivating Saudi talents, transfer of BGI’s mature technology and capacity to empower Saudi Arabia’s medical infrastructure, enabling genetic disease prevention, enriching the Saudi genetic database to improve accuracy of genetic diagnosis, and enabling big data and AI capabilities.

 

Al Amoudi noted that with such capabilities, Genalive aims to support the research, development and innovation strategy and the objectives of the Health Sector Transformation Program. Keeping in mind that genetics and biotechnology are of particular importance in the kingdom, this urged Genalive to establish several research partnerships with different institutions in order to offer comprehensive solutions and latest technology, while supporting bioinformatics and scientific research.

 

In addition, Genalive CEO stressed that the company aspires to support the realization of Saudi Vision 2030 and provide a world-class model of advanced diagnostics and trans-omics laboratory services, clarifying that “Omics” are tools that allow us to study the genetic makeup then measure and classify different biomolecules to assess the human condition in wellness and illness. They are powerful contributors to our knowledge network and our ability to prevent and treat disease and apply personalized medicine.

 

Finally, Dr. Al-Amoudi unveiled that Genalive Medical Company has been established as a strategic partnership between Arabian International Healthcare Holding Company (Tibbiyah) and BGI Group. This partnership was created to support the implementation of the Health Sector Transformation Program which constitutes one of the Kingdom’s Vision 2030 key program, that seeks to restructure the health sector to best serve both the individual and the society and to ensure maximum level of attention to public health by promoting disease prevention, and facilitating access to health care services with improved both efficiency and quality.